Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Pharmacokinetic Study of HRS-8829
Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Summary
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction(DDI)
Official title: Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
83
Start Date
2025-08-06
Completion Date
2026-01-12
Last Updated
2026-04-28
Healthy Volunteers
Yes
Conditions
Interventions
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.
HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.
HRS-8829;Edaravone injection
Subject will receive HRS-8829 at dose level 2. Subject will receive edaravone injection at dose level 5.
Locations (1)
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China